Turkey Aims To End Government Monopoly By Allowing Competition To Curb Drug Costs And Shortages
This article was originally published in PharmAsia News
Executive Summary
Turkey’s Minister of Health has flagged the end of a monopoly on drug import licenses for the Turkish Union of Pharmacists, and is working out details of an open tender process to include private firms.
You may also be interested in...
Medtech Procurement A Victim Of Turkey’s Ongoing Economic Troubles
The devaluation of the Turkish Lira since May is making imports of medical devices more expensive and putting hospital procurement under renewed pressure. The local medtech industry associations TUMDEF and ARTED describe the problems ̶ and the solutions ̶ to Medtech Insight.
A Bright Moment At Last In Turkish Medtech Debt Payments Saga
Turkish medtechs’ demands for payment of their outstanding hospital debts went unheeded in 2021, but the government has finally started a payment process. It is not evenly applied, and has started in a small way, but the industry feels encouraged on more than one count.
Turkish Health System Slides Into Crisis After Devaluation Of Lira
Amid delays in surgical operations caused by shortages of equipment and medtech companies demanding payment of outstanding hospital debts, a strong devaluation of the Turkish lira has put the local health care system on a crisis footing.